| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.29 | 0.09 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.29 | 0.3 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.29 | 0.04 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.26 | 0.04 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.25 | 0.02 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.24 | 0.08 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.23 | 0.4 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.23 | 0.06 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.21 | 0.01 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.1 |